FUNDING
Company Profile
Clinical-stage biopharmaceutical company developing best-in-disease therapies for vision-threatening eye diseases, including a VEGF/Ang2 bispecific antibody in Phase 3 for DME and wet AMD.
Founded 2023Chicago, Illinois$430M raised
Investors
ARCH Venture PartnersTCGX (TCG Crossover)Andreessen HorowitzMubadala CapitalMonograph CapitalBlackstone Multi-Asset InvestingCommodore CapitalRA Capital Management
Compare with
Funding & Valuation History
from our coverage| Date | Event | Amount | Valuation | Source |
|---|---|---|---|---|
| Jun 25, 2026 | Ollin Biosciences Raises $330M Series B for Next-Generation Eye Disease Therapies | $330M | — | Story → |
Ollin Biosciences FAQ
- How much has Ollin Biosciences raised?
- Ollin Biosciences has raised approximately $430M in total funding to date.
- Is Ollin Biosciences publicly traded?
- No. Ollin Biosciences is privately held.
- Who are Ollin Biosciences's investors?
- Ollin Biosciences's investors include ARCH Venture Partners, TCGX (TCG Crossover), Andreessen Horowitz, Mubadala Capital, Monograph Capital, Blackstone Multi-Asset Investing, Commodore Capital, RA Capital Management.
Coverage Timeline
newest firstAll Coverage
FUNDING$330M
Ollin Biosciences Raises $330M Series B to Advance Its Therapeutics Pipeline
Ollin Biosciences raised a $330 million Series B co-led by TCG Crossover and Arch Venture Partners, one of the largest life-sciences rounds of the week. The financing pushes its therapeutics pipeline deeper into clinical development and adds to mounting evidence that biotech's capital markets have reopened in force alongside the AI boom.
FUNDING
Ollin Biosciences Raises $330M Series B for Next-Generation Eye Disease Therapies
FUNDING$330M
Ollin Biosciences Raises $330M Series B for Next-Generation Eye Disease Therapies
Ollin Biosciences raised a $330 million Series B led by TCG Crossover and ARCH Venture Partners to advance its pipeline of ophthalmic therapies, one of the largest biotech rounds of the period. The deal is a reminder that even amid AI's dominance of headlines and capital, large therapeutic biotech rounds remain a major and resilient corner of venture funding.